on Date: June 20, 2019 (v2) .
Brief Title : Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor .
Official Title : A Phase I/Ib Pilot Study of Combined Trabectedin and Venetoclax in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor .
Study Status
Record Verification : June 2019 .
Overall Status : Recruiting .
Study Start : June 18, 2019 .
Primary Completion : April 9, 2020 [Anticipated] .
Study Completion : April 9, 2020 [Anticipated] .
Sposor/Collaborators
Sponsor : M.D. Anderson Cancer Center .
Responsible Party : Sponsor .
Collaborators : National Cancer Institute (NCI) .
Oversight
U.S. FDA-regulated Drug : Yes .
****************************
Más información sobre Venetoclax :
